Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M

Theravance Biopharma, Inc.

2024-Q1 EPS reported -$0.24 revenue$14,503,000

Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.
Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.
YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.
Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.
Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.

Period: the first quarter of 2024
Revenue: Total revenue for the first quarter of 2024 was $14.5 million
Net income: Net loss was $11.7 million
Result: reported results

Exact text from the filing

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.